Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC1s-CTL Cell Therapy for Renal Cell Carcinoma
NCT02787915Phase 2Unknown
- Sponsor
- Xuzhou Medical University
- Start
- Sep 2016
- Primary completion
- Aug 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 2, open-label, single-arm trial of tumor polypeptide pool induced DC-CTL cells in renal cell carcinoma (RCC), sponsored by Xuzhou Medical University. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 24 weeks. Status: unknown.
02
Drugs
tumor polypeptide pool induced DC-CTL cells
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02787915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02787915.